[Public Notice+] Coson Secures Majority Shareholder Status in DesignCell

[Asia Economy Reporter Eunmo Koo] Koson announced on the 16th that it has disclosed the results of issuing convertible bonds worth approximately 11.5 billion KRW and secured the position of the largest shareholder of the bio company DesignCell, marking its first step into the bio industry.

DesignCell has accumulated expertise primarily through research focused on treating intractable neurological diseases. It succeeded in developing 'functional gene-loaded stem cells' and holds numerous domestic and international patents related to various pipelines and treatments for intractable neurological diseases, including brain disorders such as dementia, stroke, cerebral palsy, as well as glaucoma, multiple sclerosis, and arthritis. The bio research company has established branches not only in Korea but also in China and Vietnam, actively pursuing overseas expansion.

Additionally, it succeeded in developing 'exosome-rich conditioned medium,' a substance that delivers to target cells or damaged areas to regulate bodily functions and regenerate cells and tissues. In particular, DesignCell succeeded in extracting 50 to 100 times more exosomes compared to existing methods, planning to develop treatments for intractable diseases by utilizing functions such as inflammation suppression, tissue repair, and functional recovery. This technology can also be extended to cosmetics and is expected to be integrated into Koson's new product development.

The company stated, “DesignCell has received multiple collaboration proposals from various overseas companies and hospitals for treating brain disorders such as dementia, stroke, and cerebral palsy using 'functional gene-loaded stem cells,' as well as for treating glaucoma, multiple sclerosis, and arthritis using 'exosome-rich conditioned medium.' Therefore, visible results are expected soon.”

This content was produced with the assistance of AI translation services.